SynthesisBMC cancer2026

CDK4/6 inhibitors combined with fulvestrant for the treatment of HR+/HER2-advanced or metastatic breast cancer: a Bayesian network meta-analysis.

Yanmin Deng et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.